Efficacy and safety of distamab vedotin combined with carboplatin and bevacizumab for HER2-expressing platinum-sensitive ovarian cancer with prior PARPi treatment.
Authors: Huijuan Yang, Wei Jiang, Xuan Pei, Yi Wang, Shuai Liu, Yi Fu, Yufan Cheng, Shaoxian Tang